Results 31 to 40 of about 13,589 (222)
Weight changes among Depo-medroxyprogesterone acetate acceptors in Sagamu, Southwest Nigeria [PDF]
, 2021 Background: Depo-medroxyprogesterone acetate is a highly effective injectable contraceptive. Weight gain is a commonly reported side effect that makes women to discontinue the contraceptive method.
Akadri, A. A., Odelola, O. I
core
Inhibitory effect of medroxyprogesterone acetate on human liver cytochrome P450 enzymes [PDF]
, 2006 Objective: Medroxyprogesterone acetate (MPA), frequently used in contraception and chemotherapy, was involved in a report of drug-drug interaction (DDI) when co-administrated with phenytoin, doxifluridine and cyclophosphamide.
Hao, Da-Cheng +5 more
core +1 more source
Energy Expenditure And Anthropometric Measurements In New Users Of Depot Medroxyprogesterone Acetate [PDF]
, 2016 Objective The objective of this study was to assess energy expenditure and the anthropometric profile of women during the first year of use of depot medroxyprogesterone acetate contraception.
Waleska Oliveira; Bahamondes +6 more
core +1 more source
AJOG Global ReportsObjective: The purpose of this paper is to consolidate existing evidence and identify knowledge and research gaps on the bone health effects of progestin-only oral contraception, injectables, hormonal intrauterine devices, and implants.
Blake Erhardt-Ohren, MPH +2 more
doaj +1 more source
Healthcare in Low-resource Settings, 2023 Depot medroxyprogesterone acetate (DMPA) is a contraceptive method that prevents ovulation and reduces endometrial thickness. This study aimed to investigate the influence of Vigna unguiculata (VU) on estrogen receptor-α expression and endometrial ...
Rizki Fitrianingtyas +5 more
doaj +1 more source
Body Weight And Body Composition Of Depot Medroxyprogesterone Acetate Users [PDF]
, 2015 Objectives Weight gain is a concern with the contraceptive depot-medroxyprogesterone acetate (DMPA); however, this issue remains controversial. The objective of this study was to compare body weight (BW) and body composition (BC) in DMPA and copper ...
Monteiro I. +4 more
core +1 more source
Effects of medroxyprogesterone acetate on gestation in mink [PDF]
Reproduction, 1982 Summary. Mink ovariectomized 14 days after the first of two matings received injections of 2 mg MPA, the same MPA treatment + an oestradiol-17β implant or no replacement therapy. Some mink were ovariectomized after implantation and given a single dose of 2 mg MPA or no replacement therapy.
B D, Murphy, P W, Concannon, H F, Travis
openaire +2 more sources
The Role of Subcutaneous Depot Medroxyprogesterone Acetate in Equitable Contraceptive Care [PDF]
, 2021 Since the beginning of the coronavirus disease 2019 (COVID-19) pandemic, health care professionals have made swift accommodations to provide consistent and safe care, including emphasizing remote access to allow physical distancing.
Roe, Andrea H +13 more
core +1 more source
Hormonal Contraceptives: What if Exposed During Pregnancy?
Erciyes Medical Journal, 2019 Objective: Hormonal contraceptives are contraindicated in pregnancy. However, some women may become pregnant while using contraceptives to prevent pregnancy.
Duygun Altıntaş Aykan, Yusuf Ergün
doaj +1 more source
Pelvic venous disorders in women: Diagnosis and management for gynecologists
International Journal of Gynecology &Obstetrics, EarlyView.Abstract Pelvic venous disorders (PeVD) are an underrecognized yet significant cause of chronic pelvic pain (CPP) in reproductive‐aged women, characterized by venous reflux, obstruction, or both. This clinical opinion provides a practical overview of PeVD for gynecologists, outlining its pathophysiology, common presentations, diagnostic approach, and ...
Tiffany Ni +5 more
wiley +1 more source